Group 1 - The core point of the article is that Kexin Technology (SZ 300565) held its seventh board meeting on October 22, 2025, to review the third quarter report for 2025 [1] - Kexin Technology's revenue composition for the first half of 2025 is entirely from the manufacturing of communication network physical connection equipment, accounting for 100% [1] - As of the report, Kexin Technology has a market capitalization of 3 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing deals this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]

Group 1 - The company, Kexin Technology, announced its fifth board meeting for 2025, held on August 20, 2025, in Shenzhen, where it reviewed the semi-annual report and related documents [1] - For the first half of 2025, Kexin Technology reported that its revenue was entirely derived from the manufacturing of communication network physical connection equipment, accounting for 100.0% of its revenue [1] - As of the report, Kexin Technology has a market capitalization of 3.3 billion yuan [1]